A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
17actual
Sites
29
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-25 | actual | When the study began enrolling |
| Primary completion | 2025-11-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-03 | estimated | The whole study's end, after follow-up |
| First posted | 2022-10-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Plaque Psoriasis
Intervention
- Drug: Apremilast — also filed as AMG 407, Otezla
Primary outcome
what the primary-completion date above is the date OFAchievement of a static Physician Global Assessment (sPGA) score of clear (0) or almost clear (1) with at least 2 points reduction from baseline at Week 16
measured Week 16
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed